AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--( BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2025.
“This quarter, we continued to execute across a diverse pipeline spanning multiple, potentially high impact projects in infectious diseases and oncology, leveraging our boron chemistry platform to address areas of high unmet need. These programs reflect our commitment to delivering transformative therapies, each having potential to meaningfully add shareholder value within our cash runway,” said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. “Our program studying oral AN2-502998 for Chagas disease is progressing through a Phase 1 first-in-human clinical trial, and planning for a subsequent Phase 2 proof-of-concept study is underway with our collaborators at Drugs for Neglected Diseases initiative (DNDi). In oncology, we expect our two lead programs to enter development in 2026, each with the potential to meaningfully impact solid-tumor cancers. We’ve also entered into a collaboration with GSK focused on TB, where our work is supported by a third year of funding from the Gates Foundation. This initiative reflects our commitment to applying boron chemistry to a disease that continues to impact a quarter of the world’s population.”
Third Quarter & Recent Business Updates:
Chagas Disease
Boron Chemistry Pipeline
Nontuberculous Mycobacteria (NTM) Lung Disease Caused by M. abscessus
Melioidosis
Global Health
Selected Third Quarter Financial Results
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM lung disease caused by M. abscessus and melioidosis, along with programs focused on targets in oncology and other infectious diseases. We are committed to delivering high-impact drugs to patients that address critical medical needs and improve health outcomes. For more information, please visit our website at www.an2therapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the potential and competitive advantage of the Company’s boron chemistry platform; high-impact nature of the Company’s clinical programs; the potential for an IIT in M. abscessus disease to proceed and whether data from such a trial could provide human proof of concept in that condition; the Company’s approach to capital allocation and the availability of and plans to use non-dilutive funding, including the possibility that the U.S. government will not fund the Phase 2 and other future melioidosis trials; expectations regarding the Company’s clinical trials and IIT trials, including initiation, enrollment, conduct and the timing of data and related announcements; whether and to what extent NHP models de-risk translation to human efficacy in Chagas disease; market and sales potential; priority review voucher eligibility and registrational pathways; cash runway; continued global health programs; and other statements that are not historical fact. These statements are based on AN2’s current estimates, expectations, plans, objectives and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: AN2’s ability to implement its plans for its internal boron chemistry platform and pipeline programs; timely enrollment of patients in AN2’s clinical trials and IITs; disruptions at the FDA and other government agencies caused by funding shortages, staff reductions and statutory, regulatory and policy changes; AN2’s ability to procure sufficient supply of its product candidates for its clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results, the ability of particular preclinical models in non-human primates to predict safety and efficacy in humans; significant adverse events, toxicities or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; continued government funding of AN2’s development program for melioidosis; AN2’s ability to obtain, maintain or protect intellectual property rights related to its current and future product candidates; implementation of AN2’s strategic plans for its business and product candidates; the sufficiency of AN2’s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts and other risks, including those described under the heading “Risk Factors” in AN2’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (SEC). These filings, when made, are available on the investor relations section of AN2’s website at www.an2therapeutics.com and on the SEC’s website at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law.
AN2 THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Operating expenses:
Research and development
$
7,000
$
8,287
$
17,890
$
35,091
General and administrative
3,040
3,484
10,903
10,856
Restructuring charge
—
2,243
—
2,243
Total operating expenses
10,040
14,014
28,793
48,190
Loss from operations
(10,040
)
(14,014
)
(28,793
)
(48,190
)
Interest income
687
1,267
2,329
4,390
Other income
—
—
—
1
Net loss attributable to common stockholders
$
(9,353
)
$
(12,747
)
$
(26,464
)
$
(43,799
)
Net loss per share attributable to common stockholders, basic and diluted
$
(0.31
)
$
(0.43
)
$
(0.88
)
$
(1.47
)
Weighted-average number of shares used in computing net loss per share, basic and diluted
30,276,230
29,841,169
30,168,221
29,809,839
Other comprehensive loss:
Unrealized loss on investments
39
139
33
(163
)
Comprehensive loss
$
(9,314
)
$
(12,608
)
$
(26,431
)
$
(43,962
)
AN2 THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
September 30,
2025
(unaudited)
December 31,
2024
Assets
Current assets:
Cash and cash equivalents
$
18,003
$
21,351
Short-term investments
43,918
62,267
Prepaid expenses and other current assets
2,095
2,644
Long-term investments
3,219
5,021
Other assets, long-term
—
804
Total assets
$
67,235
$
92,087
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
2,226
$
3,317
Other current liabilities
4,632
6,921
Total liabilities
6,858
10,238
Stockholders’ equity
60,377
81,849
Total liabilities and stockholders’ equity
$
67,235
$
92,087